Werewolf Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets (unaudited)
(amounts in thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $139,189 | $134,343 |
| Prepaid expenses and other current assets | 2,320 | 2,677 |
| Other receivables | 775 | 1,350 |
| Total current assets | 142,284 | 138,370 |
| Property and equipment, net | 7,529 | 7,958 |
| Restricted cash and cash equivalents, net of current portion | 21,027 | 21,023 |
| Operating lease right of use asset | 6,512 | 6,888 |
| Other assets | 248 | 594 |
| Total assets | $177,600 | $174,833 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,594 | $1,336 |
| Accrued expenses and other current liabilities | 6,215 | 8,860 |
| Operating lease liability, current | 1,236 | 1,608 |
| Deferred revenue, current | 502 | 907 |
| Note payable, current | 11,667 | 6,667 |
| Total current liabilities | 21,214 | 19,378 |
| Operating lease liability, net of current portion | 10,620 | 10,992 |
| Deferred revenue, net of current portion | 431 | 433 |
| Note payable, net of discount, issuance costs, and current portion | 27,748 | 32,656 |
| Total liabilities | 60,013 | 63,459 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 43,282,371 and 39,107,048 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 4 | 4 |
| Additional paid-in capital | 477,849 | 455,443 |
| Accumulated deficit | (360,266) | (344,073) |
| Total stockholders’ equity | 117,587 | 111,374 |
| Total liabilities and stockholders’ equity | $177,600 | $174,833 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.